Announcements Trials

Browse Landscape

Status

Sponsor Class

Study Type

Observational 1

Sponsor

Conditions

Diabetes Mellitus, Type 2 1

Interventions

Paclitaxel 336 pembrolizumab 332 Carboplatin 329 Cisplatin 276 Gemcitabine 264 Docetaxel 251 Bevacizumab 239 Nivolumab 230 Pemetrexed 210 Rituximab 183 Dexamethasone 183 Cyclophosphamide 169 Capecitabine 169 Trastuzumab 149 Fluorouracil 147 Ipilimumab 121 atezolizumab 117 Prednisone 117 Erlotinib Hydrochloride 116 Oxaliplatin 109 Cetuximab 104 Sunitinib 101 Leucovorin 97 Doxorubicin 97 Lenalidomide 93 Irinotecan 89 130-nm albumin-bound paclitaxel 84 Bortezomib 77 durvalumab 76 Azacitidine 72

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

INDUSTRY × Has results × empagliflozin × Clear all

NCT03464045 2025-04-20

Empa PASS on Urinary Tract Malignancies

Boehringer Ingelheim

344,995 enrolled 12 charts

Diabetes Mellitus, Type 2

Data powered by HemOnc (CC BY 4.0) Colophon ⚡